(Total Views: 595)
Posted On: 06/15/2021 11:13:40 PM
Post# of 153886
Re: Riztheinvestor #93787
I actually remember Dr. Kelly being quite candid about a CEO search in that interview. Again, this was atleast several months ago.
Regardless, I’m convinced it’s a total mistake to make any change in management. The company must stay focused on the clinical trials. And we can't take the risk of putting in management who may sell us out for cheap.
Leronlimab is an absolute blockbuster across multiple indications. Let the data talk, and it will!
Remarkably, the positive animal data with Leronlimab (e.g., with cancer) has been an incredible predictor of its efficacy in humans. Personally, I can’t wait for the NASH data in humans (also tremendous animal data with Leronlimab).
NASH market size is expected to be $20 billion in 2027, and there is no approved drug yet!
Regardless, I’m convinced it’s a total mistake to make any change in management. The company must stay focused on the clinical trials. And we can't take the risk of putting in management who may sell us out for cheap.
Leronlimab is an absolute blockbuster across multiple indications. Let the data talk, and it will!
Remarkably, the positive animal data with Leronlimab (e.g., with cancer) has been an incredible predictor of its efficacy in humans. Personally, I can’t wait for the NASH data in humans (also tremendous animal data with Leronlimab).
NASH market size is expected to be $20 billion in 2027, and there is no approved drug yet!
(6)
(0)
